The partnership will help visitors to Bayer websites for Aspirin, Aleve, Midol, Cenesten and Iberogast to access Ada’s intelligent symptom assessment platform.

Using an AI-based health assessment platform, Berlin-based Ada Health assists users in identifying the correct care, based on their individual requirements, risk factors and symptoms.

The free app provides guidance via an AI chatbot which asks users targeted questions that generate data-driven options and suggestions for the next steps in seeking healthcare.

WHY IT MATTERS

The partnership offers a digital solution so that people can be more proactive about preventative healthcare.

Digital health tools provide personalised insights and actionable medical guidance. People can look for guidance on health issues they may think too insignificant to take to a doctor.

Timely detection of diseases is one of the biggest challenges in guiding patients to appropriate care, with under-diagnosis and long patient journeys to diagnosis.

Shortening the time to diagnosis by providing medical guidance by using digital data can support the prediction and prevention of diseases.

THE LARGER TREND

The app essentially works like a WhatsApp chat with a trusted family doctor or medical professional, but is available 24/7.

More than 11 million people worldwide have used Ada Health, completing over 25 million personal health assessments.

The symptom assessment app currently supports ten languages, but in future, the aim is for a billion people to use the technology. 

The app can be downloaded directly, or for people in the US, UK or Germany, and it can be accessed via the Aspirin, Aleve, Midol, Canesten and Iberogast websites.

In May, Ada Health clinched a $90 million (€79.7M) Series B round of funding from Bayer's investment arm, Leaps by Bayer.

ON THE RECORD

“Ada’s technology is based on a custom-built reasoning engine and a highly comprehensive medical knowledge base, covering thousands of conditions. In fact, in a recent vignettes study testing the eight most popular online symptom assessment apps, Ada was proven to have the most comprehensive condition coverage, providing a condition suggestion 99% of the time, with high medical accuracy and safety of advice,” Vanessa Lemarié, Ada Health’s Chief Client Officer told MobiHealthNews.

“When it comes to women’s intimate health, for example, many feel embarrassed or uncomfortable reaching out to their GP or healthcare professional to discuss their symptoms. But with Ada, they can access trusted, high quality health information from the comfort of their own home, via a simple, easy-to-use online tool,” Lemarié added.

“One of the exciting frontiers in healthcare is giving people the right tools, information, advice and medicines to move from a reactive to a proactive approach to their own health,” said David Evendon-Challis, Chief Scientific Officer of Bayer’s Consumer Health division.